D. Boral Capital Reiterates “Hold” Rating for Citius Pharmaceuticals (NASDAQ:CTXR)

Citius Pharmaceuticals (NASDAQ:CTXR)‘s stock had its “hold” rating reiterated by research analysts at D. Boral Capital in a research note issued on Friday,Benzinga reports.

Separately, HC Wainwright reiterated a “buy” rating and set a $4.00 target price on shares of Citius Pharmaceuticals in a research report on Tuesday, November 12th.

Citius Pharmaceuticals Stock Up 51.5 %

Shares of Citius Pharmaceuticals stock opened at $0.20 on Friday. The firm has a market cap of $36.63 million, a PE ratio of -0.56 and a beta of 1.66. Citius Pharmaceuticals has a twelve month low of $0.11 and a twelve month high of $1.07. The business has a 50-day moving average price of $0.40 and a 200 day moving average price of $0.58.

Citius Pharmaceuticals’s stock is set to reverse split before the market opens on Tuesday, November 26th. The 1-25 reverse split was announced on Friday, November 22nd. The number of shares owned by shareholders will be adjusted after the market closes on Monday, November 25th.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Virtu Financial LLC purchased a new stake in Citius Pharmaceuticals during the 3rd quarter worth approximately $50,000. Geode Capital Management LLC boosted its stake in shares of Citius Pharmaceuticals by 14.1% in the third quarter. Geode Capital Management LLC now owns 1,878,953 shares of the company’s stock worth $941,000 after acquiring an additional 232,656 shares during the last quarter. XTX Topco Ltd purchased a new stake in shares of Citius Pharmaceuticals during the third quarter worth approximately $47,000. Miller Investment Management LP raised its stake in Citius Pharmaceuticals by 99.3% in the 3rd quarter. Miller Investment Management LP now owns 99,640 shares of the company’s stock valued at $50,000 after purchasing an additional 49,640 shares during the last quarter. Finally, Arkadios Wealth Advisors lifted its holdings in Citius Pharmaceuticals by 33.3% in the 3rd quarter. Arkadios Wealth Advisors now owns 200,000 shares of the company’s stock valued at $100,000 after purchasing an additional 50,000 shares in the last quarter. 16.88% of the stock is owned by hedge funds and other institutional investors.

Citius Pharmaceuticals Company Profile

Citius Pharmaceuticals, Inc, a late-stage pharmaceutical company, engages in the development and commercialization of critical care products focusing on oncology products, anti-infectives products in adjunct cancer care, prescription products, and stem cell therapy. It is developing five proprietary products comprising LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma, which is in Phase 3 clinical trial; Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase 3 clinical trial; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids that is in clinical Phase 2b trial; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome.